Bergen, Norway 14.9.22
Lifecare AS (Lifecare) has signed a Letter of Intent (LOI) with InnovationsparkMainz GmbH & Co KG (IVP). On this basis Lifecare and IVP will initiate anintensive joint development of a new Lifecare manufacturing location in Mainz(Germany), with an optimized infrastructure for sensor-production. In additionto production, Lifecare intends to integrate and co-locate the existingdevelopment units Lifecare Laboratory and Lifecare NanoBioSensors at the samelocation. IVP is developing the "Mainz Innovation Park", which is situated adjacent to theUniversity of Mainz and University of Applied Sciences. Lifecare and IVP will incooperation develop up to 900 sqm in "LAB1", a modern and multifunctionalbuilding for highly specialized laboratories including service and productionareas, and office floors. Based on the initial planning and adjustments fromIVP, the building and the location have been assessed as adequately stable andhence suitable for Scanning Electron Microscopes necessary for Lifecare's sensorproduction. Lifecare and IVP will work together to optimize the space planning forproduction, laboratory and office spaces over the next three months and IVP hopeto submit the building application and agree on a long- term leasing agreementby end of 2022. The new property will be handed over to Lifecare in 2024. IVP is a joint venture between GL Kayser Immobilien and IGM, both located inMainz (Germany) and J. Molitor Immobilien GmbH in Ingelheim am Rhein (Germany).The joint venture partners hold a high level of industry and project developmentexperience, as well as a distinctive know-how for real estate in the researchand pharmaceutical sector. J. Molitor Immobilien GmbH and subsidiaries have abroad experience from development and successful realization of laboratory andresearch facilities for various institutes of the University of Mainz, BioNTechSE, Boehringer Ingelheim Pharma GmbH & Co.KG, Merck KGaA and other well-knowncompanies. Further information Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.attme.dev, +47 40 05 90 40 This information is considered to be inside information pursuant to the EUMarket Abuse Regulation and is subject to the disclosure requirements pursuantto Section 5-12 the Norwegian Securities Trading Act. This stock exchangeannouncement was published by Joacim Holter, CEO at Lifecare AS, on 14.9.2022 at7:57 CET.